OverviewChartNewsTraderScreen

L&S Knock-Out Zealand Pharma A/S/  DE000LX30PA9  /

EUWAX
11/09/2024  08:12:12 Chg.+0.14 Bid20:49:29 Ask20:49:29 Underlying Strike price Expiration date Option type
4.51EUR +3.20% 5.09
Bid Size: 2,000		 5.21
Ask Size: 2,000		 - 72.4586 EUR 31/12/2078 Call
GlobeNewswire 22/08 Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants
GlobeNewswire 15/08 Zealand Pharma Announces Financial Results for the First Half of 2024
GlobeNewswire 12/08 Zealand Pharma conference call on August 15 at 2pm CET (8am ET) to present first half 2024 financial...
GlobeNewswire 29/07 Zealand Pharma Appoints Eric Cox as Chief Commercial Officer
GlobeNewswire 26/06 Zealand Pharma announces completion of an upsized equity offering of 8.35 million new ordinary share...
GlobeNewswire 25/06 Zealand Pharma announces upsizing of previously announced equity offering from approximately USD 900...
GlobeNewswire 25/06 Zealand Pharma launches equity offering of new shares raising gross proceeds of approximately USD 90...
GlobeNewswire 20/06 Zealand Pharma announces positive topline results from the Phase 1b 16-week multiple ascending dose ...
GlobeNewswire 07/06 Zealand Pharma announces that Boehringer Ingelheim’s survodutide demonstrates breakthrough improveme...
GlobeNewswire 07/06 Boehringer Ingelheim’s survodutide shows breakthrough improvement in liver fibrosis with no worsenin...
GlobeNewswire 06/06 Zealand Pharma announces that Boehringer Ingelheim will present positive results from Phase 2 trial ...
GlobeNewswire 31/05 Zealand Pharma announces positive CHMP opinion for dasiglucagon for treatment of severe hypoglycemia...
GlobeNewswire 29/05 Zealand Pharma to participate in upcoming healthcare investor conferences in June 2024
GlobeNewswire 23/05 Zealand Pharma announces topline results from the mechanistic investigator-led DREAM trial with low ...
GlobeNewswire 16/05 Zealand Pharma Announces Financial Results for the First Quarter of 2024
GlobeNewswire 09/05 Zealand Pharma conference call on May 16 at 2pm CET (8am ET) to present first quarter 2024 financial...
GlobeNewswire 20/03 Entera Bio Announces Robust Pharmacokinetic Data for First-in-Class Oral GLP-2 Peptide Tablet Treatm...
GlobeNewswire 01/03 Zealand Pharma to Participate in TD Cowen’s 44th Annual Health Care Conference
GlobeNewswire 27/02 Zealand Pharma Announces Financial Results for the Full Year 2023
TeleTrader 26/02 Zealand Pharma soars 30% on positive weight-loss drug results
GlobeNewswire 26/02 Zealand Pharma announces Boehringer Ingelheim survodutide Phase 2 trial shows 83% of adults treated ...
GlobeNewswire 26/02 Survodutide Phase II trial shows 83% of adults treated achieved groundbreaking results in liver dise...
GlobeNewswire 20/02 Zealand Pharma conference call on February 27 at 2pm CET (8am ET) to present full year 2023 financia...
GlobeNewswire 19/01 Zealand Pharma major shareholder announcement: J O Hambro Capital Management
GlobeNewswire 17/01 Zealand Pharma major shareholder announcement: J O Hambro Capital Management